Allogene Therapeutics Names Benjamin M. Beneski as CTO

Allogene Therapeutics Promotes New Chief Technical Officer

Allogene Therapeutics, Inc. (NASDAQ: ALLO), a clinical-stage biotechnology firm, has announced the promotion of Benjamin M. Beneski to Senior Vice President and Chief Technical Officer (CTO). This decision comes as the company looks to continue advancing its allogeneic CAR T (AlloCAR T) products aimed at treating cancer and autoimmune diseases.

Transitioning Leadership

Mr. Beneski's promotion marks a significant transition within the company as he takes over from Tim Moore, who has played a vital role for two years. Moore's leadership and contributions have been instrumental in progressing Allogene’s initiatives within the cell and gene therapy landscape. His departure is felt deeply, with the team expressing gratitude for his unwavering commitment and mentorship.

In his new role, Mr. Beneski will guide Allogene’s technical operations, capitalizing on his extensive experience in biologics manufacturing and process development. His expertise is anticipated to help propel the company's innovative projects and strengthen its operational framework.

Recognizing Beneski's Expertise

David Chang, M.D., Ph.D., the President and CEO of Allogene, shared his enthusiasm for this leadership change. He emphasized Mr. Beneski's instrumental role in shaping the company's manufacturing strategy, highlighting his ability to foster innovative solutions and build high-performing teams. This recognition reflects the trust placed in Beneski to lead Allogene into its next phase of growth.

A Glimpse into Mr. Beneski's Background

Mr. Beneski brings a wealth of experience to his new position. He joined Allogene in 2019 as Executive Director and Plant Manager, during which he spearheaded the design and launch of Cell Forge 1, the company's advanced manufacturing facility. His trajectory within the organization has included roles that have progressively increased in responsibility, heralding significant contributions to manufacturing support and product development.

Industry Experience

With over two decades dedicated to biologics manufacturing and technical operations, Mr. Beneski has held key positions at reputable organizations, including Vir Biotechnology and Amgen. His solid educational background, with an MBA from Northeastern University and a Chemical Engineering degree from Stevens Institute of Technology, complements his extensive industry expertise.

About Allogene Therapeutics

Headquartered in South San Francisco, Allogene Therapeutics is pioneering advances in allogeneic chimeric antigen receptor T cell (AlloCAR T) products. The company is driven by a mission to develop an innovative pipeline of “off-the-shelf” CAR T cell candidates, aiming for more reliable and scalable cell therapy options accessible to a broader patient population. Allogene aims to redefine how cell therapies are delivered, striving to make them more readily available on demand.

For further information about Allogene Therapeutics and updates on their developments, follow @AllogeneTx on social media platforms or visit their website.

Frequently Asked Questions

Who is the new Chief Technical Officer at Allogene Therapeutics?

Benjamin M. Beneski has been promoted to Chief Technical Officer.

What role did Tim Moore play in Allogene Therapeutics?

Tim Moore served as CTO for two years, contributing significantly to the company’s initiatives in cell and gene therapy.

What is Benjamin Beneski's experience in the industry?

Mr. Beneski has over 20 years of experience in biologics manufacturing, including leadership roles at Vir Biotechnology and Amgen.

What advancements does Allogene Therapeutics focus on?

Allogene Therapeutics focuses on developing allogeneic CAR T products aimed at treating cancer and autoimmune diseases.

How can I learn more about Allogene Therapeutics?

You can visit the company's website or follow them on social media for updates and information.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.